Jazz Pharmaceuticals plc (JAZZ) Stock Analysis
A live, multi-source view of Jazz Pharmaceuticals plc (JAZZ): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
Sector: Healthcare · Industry: Biotechnology · Ireland · 2,890 employees · jazzpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Jazz Pharmaceuticals plc (JAZZ) had a market capitalization of $16.02B, a trailing P/E of 17.0 (forward 9.6) and a beta of 0.36; the shares traded in a 52-week range of $123.88 – $266.38 (90.1% over the year).
- Market cap
- $16.02B
- Enterprise value
- $18.23B
- Trailing P/E
- 17.0
- Forward P/E
- 9.6
- PEG ratio
- 0.96
- Price / book
- 3.33
- EPS (trailing)
- $14.56
- EPS (forward)
- $25.77
- Payout ratio
- 0.0%
- 52-week range
- $123.88 – $266.38
- 52-week change
- 90.1%
- Beta
- 0.36
- Average volume
- 902,550
- Shares outstanding
- 64.9M
- Short % of float
- 5.73%
- Profit margin
- 20.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Jazz Pharmaceuticals plc (JAZZ) last closed at $246.81 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price -1.2% versus its 20-day average, 20-day versus 50-day average spread +0.3%, MACD histogram -0.92.
Sentiment inputs: 80% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 81/100.
Next scheduled company event: in 57 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for JAZZ in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
JAZZ has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Jazz Pharmaceuticals plc (JAZZ) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell JAZZ.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.